NO20081393L - Hydroksysubstituerte 1H-imidazopyridiner og metoder - Google Patents

Hydroksysubstituerte 1H-imidazopyridiner og metoder

Info

Publication number
NO20081393L
NO20081393L NO20081393A NO20081393A NO20081393L NO 20081393 L NO20081393 L NO 20081393L NO 20081393 A NO20081393 A NO 20081393A NO 20081393 A NO20081393 A NO 20081393A NO 20081393 L NO20081393 L NO 20081393L
Authority
NO
Norway
Prior art keywords
methods
hydroxy
substituted
compounds
imidazopyridines
Prior art date
Application number
NO20081393A
Other languages
English (en)
Inventor
Jr Joseph F Dellaria
William H Moser
Matthew R Radmer
George W Griesgraber
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20081393L publication Critical patent/NO20081393L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det beskrives hydroksysubstituerte 1H-imidazo[4,5-c]pyridin-4-aminer, med en hydroksysubstituent i 2-posisjon. Det beskrives videre farmasøytiske preparater inneholdende disse forbindelser. Det beskrives metoder for fremstilling av forbindelsene, deres mellomprodukter. Det beskrives videre metoder for bruk av forbindelsene som immunomodulatorer, for å indusere cytokinbiosyntese i dyr og ved behandling av sykdommer som inkluderer virale og neoplastiske sykdommer.
NO20081393A 2005-09-02 2008-03-17 Hydroksysubstituerte 1H-imidazopyridiner og metoder NO20081393L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71370405P 2005-09-02 2005-09-02
PCT/US2006/034427 WO2007028129A1 (en) 2005-09-02 2006-09-01 Hydroxy substituted 1h-imidazopyridines and methods

Publications (1)

Publication Number Publication Date
NO20081393L true NO20081393L (no) 2008-05-28

Family

ID=37561219

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081393A NO20081393L (no) 2005-09-02 2008-03-17 Hydroksysubstituerte 1H-imidazopyridiner og metoder

Country Status (20)

Country Link
US (2) US20100152230A1 (no)
EP (1) EP1924581A1 (no)
JP (1) JP4584335B2 (no)
KR (1) KR20080031496A (no)
CN (1) CN101253173A (no)
AU (1) AU2006287157A1 (no)
BR (1) BRPI0615250A2 (no)
CA (1) CA2620933A1 (no)
CR (1) CR9781A (no)
EA (1) EA200800396A1 (no)
EC (1) ECSP088225A (no)
IL (1) IL189262A0 (no)
MA (1) MA29759B1 (no)
MX (1) MX2008002414A (no)
NO (1) NO20081393L (no)
RS (1) RS20080128A (no)
SV (1) SV2009002832A (no)
TN (1) TNSN08099A1 (no)
WO (1) WO2007028129A1 (no)
ZA (1) ZA200801645B (no)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
BRPI0412902A (pt) 2003-08-12 2006-09-26 3M Innovative Properties Co compostos contendo imidazo substituìdo por oxima
ES2406730T3 (es) 2003-08-27 2013-06-07 3M Innovative Properties Company Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
CA2537763A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
RU2412942C2 (ru) 2003-10-03 2011-02-27 3М Инновейтив Пропертиз Компани Оксизамещенные имидазохинолины, способные модулировать биосинтез цитокинов
JP2007508305A (ja) 2003-10-03 2007-04-05 スリーエム イノベイティブ プロパティズ カンパニー ピラゾロピリジンおよびその類似物
AU2004291101A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
EP1682544A4 (en) 2003-11-14 2009-05-06 3M Innovative Properties Co HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS
MY161812A (en) 2003-11-25 2017-05-15 3M Innovative Properties Co Substituted imidazo ring systems and methods
EP1701955A1 (en) 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
AU2004312508A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
AU2005228150A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
JP5543068B2 (ja) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
CA2602083A1 (en) 2005-02-09 2006-08-09 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
AU2006212765B2 (en) 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
CA2597446A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
CA2598437A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
WO2006091567A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
CA2598695A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
EP1863814A1 (en) 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
AU2006287270A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
CA2628131C (en) 2005-11-04 2012-03-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
WO2007093901A1 (en) * 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
US8178539B2 (en) 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US20100120799A1 (en) 2007-02-19 2010-05-13 Smithkline Beecham Corporation Purine derivatives as immunomodulators
EP1997805A1 (en) * 2007-06-01 2008-12-03 Commissariat à l'Energie Atomique Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans
EP2188280B1 (en) * 2007-08-03 2011-03-09 Pfizer Limited Imidazopyridinones
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010018130A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
BRPI0917013A2 (pt) 2008-08-11 2016-02-16 Glaxosmithkline Llc métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
WO2011025938A2 (en) 2009-08-28 2011-03-03 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
SI2491035T1 (sl) * 2009-10-22 2017-10-30 Gilead Sciences, Inc. Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb
EP2534148A1 (en) 2010-02-10 2012-12-19 GlaxoSmithKline LLC Purine derivatives and their pharmaceutical uses
US9242980B2 (en) 2010-08-17 2016-01-26 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
MX347240B (es) 2011-06-03 2017-04-20 3M Innovative Properties Co Ligadores heterobifuncionales con segmentos polietilenglicol y conjugados modificadores de la respuesta inmunitaria elaborados a partir de los mismos.
JP6415979B2 (ja) 2011-06-03 2018-10-31 スリーエム イノベイティブ プロパティズ カンパニー ヒドラジノ１ｈ−イミダゾキノリン−４−アミン及びこれから調製された複合体
PL2734186T3 (pl) 2011-07-22 2019-01-31 Glaxosmithkline Llc Kompozycja
CN103450198B (zh) * 2012-05-29 2015-07-08 首都医科大学 咪唑并吡啶并咪唑-3-取代乙酸苄酯、其合成、抗肿瘤活性及应用
JP6196674B2 (ja) 2012-08-24 2017-09-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ ピラゾロピリミジン化合物
CA2890201A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
AU2013348218B2 (en) 2012-11-20 2016-10-13 Glaxosmithkline Llc Novel compounds
CA2890198A1 (en) 2012-11-20 2014-05-30 Diane Mary Coe Novel compounds
MX2017003284A (es) 2014-09-16 2017-06-28 Gilead Sciences Inc Formas solidas de modulador de receptor tipo toll.
US11306083B2 (en) 2017-12-20 2022-04-19 3M Innovative Properties Company Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
WO2021154664A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230144824A1 (en) 2020-01-27 2023-05-11 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115210236A (zh) 2020-01-27 2022-10-18 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
EP4097103A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
WO2021154663A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230127326A1 (en) 2020-01-27 2023-04-27 Bristol-Myers Squibb Company C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
KR20220132601A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
JP2023512206A (ja) 2020-01-27 2023-03-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
CN115135655B (zh) 2020-01-27 2024-07-02 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
CN117466808B (zh) * 2023-12-27 2024-03-12 烟台新药创制山东省实验室 一种6-烷基-2,4-二羟基吡啶类衍生物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ288182B6 (en) * 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
NZ329798A (en) * 1996-07-03 1999-04-29 Japan Energy Corp Purine derivatives their tautomers and salts thereof and interferon secretion inducers, antiviral agents and anticancer drugs containing the same
JP4331944B2 (ja) * 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
CZ301491B6 (cs) * 2001-04-27 2010-03-24 Eisai R&D Management Co., Ltd. Pyrazolo[1,5-a]pyridiny a léciva s jejich obsahem
NZ537054A (en) * 2002-06-07 2006-10-27 3M Innovative Properties Co Ether substituted imidazopyridines
DE602004029145D1 (de) * 2003-02-27 2010-10-28 Palau Pharma Sa Pyrazolopyridin-derivate
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
JP2005089334A (ja) * 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン化合物
JP2007522093A (ja) * 2003-09-22 2007-08-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ７−アミノアルキリデニル−複素環式キノロンおよびナフチリドン
FR2860514A1 (fr) * 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
AU2004291101A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
MY161812A (en) * 2003-11-25 2017-05-15 3M Innovative Properties Co Substituted imidazo ring systems and methods
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
WO2007093901A1 (en) * 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators

Also Published As

Publication number Publication date
JP2009507036A (ja) 2009-02-19
MA29759B1 (fr) 2008-09-01
IL189262A0 (en) 2008-06-05
JP4584335B2 (ja) 2010-11-17
ECSP088225A (es) 2008-03-26
TNSN08099A1 (fr) 2009-07-14
MX2008002414A (es) 2008-03-27
AU2006287157A1 (en) 2007-03-08
SV2009002832A (es) 2009-02-19
WO2007028129A1 (en) 2007-03-08
EA200800396A1 (ru) 2008-08-29
EP1924581A1 (en) 2008-05-28
RS20080128A (en) 2009-05-06
CN101253173A (zh) 2008-08-27
CR9781A (es) 2008-03-26
US20100152230A1 (en) 2010-06-17
BRPI0615250A2 (pt) 2011-05-10
ZA200801645B (en) 2010-08-25
US20120035209A1 (en) 2012-02-09
KR20080031496A (ko) 2008-04-08
CA2620933A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
NO20081393L (no) Hydroksysubstituerte 1H-imidazopyridiner og metoder
NO20082500L (no) Hydroksy- og alkoksysubstituerte 1H-imidazokinoliner, og fremgangsmater
WO2007106854A3 (en) Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2008030511A3 (en) Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
WO2006091568A3 (en) Hydroxyalkyl substituted imidazonaphthyridines
WO2006098852A3 (en) Hydroxyalkyl substituted imidazoquinolines
WO2006086449A3 (en) Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
NO20080785L (no) Behandling av kreft
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
WO2007131072A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2006107753A3 (en) Pyrazolopyridines and analogs thereof
BRPI0414856A (pt) imidazoquinolinas alcóxi-substituìdas
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
BRPI0413558A (pt) compostos contendo imidazo substituìdo por hidroxilamina
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
WO2006091567A3 (en) Hydroxyalkyl substituted imidazoquinoline compounds and methods
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20061157L (no) 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer
NO20084752L (no) Konjugater av aziridinayl-epotilonanaloger og farmasoytiske sammensetninger som inneholder disse
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application